Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | PKM | P14618 | 1/20 | 0.49 |
| ▸ | ACHE | P22303 | 1/20 | 0.47 |
| ▸ | GPR119 | Q8TDV5 | 11/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | BRD4 | O60885 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6953531 | 0.90 | ACHE (0.55) | KDM4EPKMACHEGPR119ALDH1A1 | |
| SCHEMBL5475624 | 0.88 | ACHE (0.53) | KDM4EPKMACHEGPR119ALDH1A1 | |
| SCHEMBL31596884 | 0.87 | GPR119 (0.53) | KDM4EPKMACHEGPR119ALDH1A1 | |
| SCHEMBL29890980 | 0.87 | ACHE (0.64) | KDM4EPKMACHEGPR119BRD4 | |
| SCHEMBL8825578 | 0.87 | ACHE (0.64) | KDM4EPKMACHEGPR119BRD4 | |
| SCHEMBL23884184 | 0.86 | ACHE (0.51) | KDM4EPKMACHEGPR119BRD4 | |
| SCHEMBL30801958 | 0.83 | DRD2 (0.49) | KDM4EPKMALDH1A1 | |
| SCHEMBL6759982 | 0.83 | KDM4E (0.55) | KDM4EPKMACHEGPR119ALDH1A1 | |
| SCHEMBL30801925 | 0.83 | DRD2 (0.49) | KDM4EPKMACHEALDH1A1 | |
| SCHEMBL12635860 | 0.83 | KDM4E (0.56) | KDM4EPKMACHEGPR119BRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6455548-B2 | FOR PROPHYLAXIS AND THERAPY OF ASTHMA, ALLERGIC RHINITIS, DERMATITIS, CONJUNCTIVITIS, ATHEROSCLEROSIS OR RHEUMATOID ARTHRITIS, INFECTION BY HIV, DELAYING OF THE ONSET OF AIDS | MERCK & CO., INC. | 2002-09-24 | — | — | US | disclosed |
| US-20020013348-A1 | 4-alkyl piperidinyl pyrrolidine modulators of chemokine receptor activity | MERCK SHARP & DOHME CORP. | 2002-01-31 | — | — | US | disclosed |
| WO-2001064216-A1 | 4-ALKYL PIPERIDINYL PYRROLIDINE MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | MERCK & CO., INC. (US) | 2001-09-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020013348-A1 | 4-alkyl piperidinyl pyrrolidine modulators of chemokine receptor activity | CCR1, CCR4, CCR3 | KDM4E 1758/4885PKM 3514/4885ACHE 4792/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.